Nebivolol 5 mg

DRUG5 trials

Sponsors

Vanderbilt University, Menarini International Operations Luxembourg SA, Ain Shams University, Kafrelsheikh University

Conditions

Arterial HypertensionHER2-positive Breast CancerHypertensionLiver CirrhosisMultiple System AtrophyPure Autonomic Failure

Phase 2

Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients

RecruitingNCT07233499

Ain Shams UniversityHER2-positive Breast Cancer

Start: 2025-01-01End: 2027-02-01Target: 56Updated: 2025-11-19

Phase 4

Effectiveness and Safety of Combination of Nebivolol and Zofenopril in Hypertensive patIents Versus Each Monotherapy

CompletedNCT05257148

Menarini International Operations Luxembourg SAHypertension

Start: 2021-05-26End: 2021-12-22Updated: 2024-09-20

Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients

CompletedNCT06104423

Menarini International Operations Luxembourg SAHypertension

Start: 2023-10-02End: 2024-02-19Updated: 2025-04-24

Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients

CompletedNCT07397481

Kafrelsheikh UniversityArterial Hypertension, Liver Cirrhosis

Start: 2024-03-01End: 2025-06-01Updated: 2026-02-09

Unknown Phase

Nebivolol in the Supine Hypertension of Autonomic Failure

CompletedNCT01044693

Vanderbilt UniversityHypertension, Multiple System Atrophy, Pure Autonomic Failure

Start: 2010-01-31End: 2014-08-31Updated: 2015-05-01